Cardiac resynchronization therapy (CRT) with multipoint left ventricular (LV) pacing [MultiPoint TM Pacing (MPP), St. Jude Medical, Sylmar, CA, USA] improves LV function and clinical response relative to conventional CRT in patients receiving a de novo device implant. We hypothesized that patients with a previously implanted conventional CRT device would receive additional benefit by switching to MPP. Patients receiving a CRT implant (Unify Quadra MP TM or Quadra Assura MP TM CRT-D and Quartet TM LV lead, St. Jude Medical) were programmed to conventional CRT (i.e. biventricular pacing with right ventricular and single LV sites) optimized by intraoperative haemodynamic measurements. After 12 months of conventional therapy, patients were reprogrammed to MPP and reevaluated at 16 months post-implant. Response to CRTwas prospectively defined as reduction in end-systolic volume (ESV) of ≥15% relative to baseline as determined by a blinded observer. Eight patients with an implanted CRT device [New York Heart Association III, ejection fraction (EF) 30 + 5%, QRS 149 + 18 ms] received 12 months of conventional CRTand were switched to MPP. After 12 months of conventional CRT, ESV reduction and EF increase relative to baseline were 218 + 12 and +5 + 4%, respectively, and six of eight (75%) patients were considered CRTresponders. After 4 months of MPP, two of two (100%) patients classified as non-responders to conventional CRT became responders with additional reduction in ESV of 233 and 220% and improvement in EF of +15 and +4%. The remaining six patients classified as responders experienced additional reduction in ESVof 213 + 21% and improvement in EF of +7 + 7% after switching to MPP. Multipoint LV pacing may provide additional improvement to LV function in patients receiving conventional CRT.
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Introduction
Symptomatic heart failure patients with prolonged QRS duration benefit from cardiac resynchronization therapy (CRT), [1] [2] [3] [4] [5] but the therapy is partly limited by the 30-40% of patients that do not respond adequately. 6, 7 Multipoint left ventricular (LV) pacing [MultiPoint TM Pacing (MPP), St. Jude Medical, Sylmar, CA, USA] is a new CRT modality that enables sequential pacing from two LV sites (LV1 and LV2) through a quadripolar LV lead and from one right ventricular (RV) site. 8 MultiPoint TM Pacing provides benefit to acute LV haemodynamics, 9,10 dyssynchrony, 11 and peak radial strain 12 and to mid-term LV function 13 beyond conventional CRT. Previous studies have focussed on the acute and chronic benefits of MPP in patients receiving de novo CRT systems. In this study, we hypothesized that patients receiving conventional CRTwould receive additional benefit by switching the CRT programming to MPP.
Methods

Patient selection
Patients implanted with a CRT device with the ability to deliver MPP (Unify Quadra MP TM or Quadra Assura MP TM , St. Jude Medical) initially programmed to conventional simultaneous biventricular pacing and who were switched to MPP were included in this analysis. Informed consent was obtained from all patients. Pre-implant inclusion criteria were an approved indication for CRT implant according to current ESC/EHRA guidelines.
14 Primary exclusion criteria were New York Heart Association (NYHA) Class IV and myocardial infarction within 40 days prior to enrolment.
Implant procedure
Patients were implanted with an MPP-enabled CRT device according to standard practice. A quadripolar LV lead (Quartet TM LV lead, St. Jude Medical) with electrodes D1, M2, M3, and P4 (distal to proximal) was targeted to a lateral, posterolateral, or anterolateral branch of the CS.
Device programming
The CRT device was programmed post-implant to simultaneous biventricular pacing with LV vector selection based on intraoperative haemodynamic measurements. 10 Pressure-volume (PV) loops were recorded during a pacing protocol including conventional CRT interventions with either a distal or a proximal LV electrode paced simultaneously with the RV. The intervention resulting in the largest relative increase in dP/dt Max was selected for programming. Device pacing settings were left unchanged for the following 12 months.
Twelve months post-implant, coinciding with the commencement of the investigation reported here, MPP was activated. Left ventricular pacing vectors for MPP were empirically chosen to pace first with the distal electrode (D1) as cathode and second from the most proximal electrode not having a high capture threshold (.5 V) or causing phrenic nerve stimulation. The sequence of pacing was defined in advance to be LV1 LV2 RV in all patients. Minimum programmable LV1-LV2 delays (5 ms) and LV2-RV delays (20 ms for Unify Quadra MP TM and 5 ms for Quadra Assura MP TM ) were empirically selected based on our previous experience. 10 No optimization of atrioventricular delay was performed for either conventional CRT or MPP.
Echocardiographic and clinical exam
Patients underwent echocardiographic and clinical evaluation prior to implant (baseline), at 12 + 1 months post-implant, and at 4 + 1 months after the switch to MPP (16 + 1 months postimplant). A transthoracic echocardiography system (iE33, Philips, Amsterdam, The Netherlands) was used to measure LVendsystolic (ESV) and end-diastolic volume (EDV) and to derive the ejection fraction (EF). Changes in LV ESV were expressed as a percent change relative to baseline or 12 months and changes in LV EF were expressed as an absolute difference relative to baseline or 12 months. We prospectively defined CRT response by the commonly used criterion of reduction in ESV of ≥15% relative to baseline.
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Statistical analysis
Comparisons between measurements after 12 months of conventional CRT and after 4 months of MPP were made with a 2-sample paired t-test. A P-value of ,0.05 was considered significant. All continuous variables are expressed as mean + standard deviation.
Results
Study population
Twelve patients were switched to MPP after 12 months of conventional CRT and underwent echocardiographic and clinical evaluation within the 4 + 1 month window. Eight patients had echocardiographic data deemed evaluable and were included in subsequent analyses. Baseline patient characteristics pre-implant from these eight patients are shown in Table 1 .
Implant procedure and post-implant device programming
The quadripolar LV lead (Quartet TM , St. Jude Medical) position was classified along the LV short axis as lateral in six patients (75%), anterolateral in one patient (13%), and posterolateral in one patient (13%). Left ventricular lead position along the LV long axis was classified as apical in two patients (25%), mid-ventricular in four patients (50%), and basal in two patients (25%). The RV lead was placed in the RV apex in five patients (63%) and in a septal position in three patients (38%). Left ventricular pacing vectors programmed post-implant for conventional CRT are shown in Table 2 .
Echocardiographic and clinical findings at 12-month follow-up
After 12-months of conventional CRT, the ESV reduction and EF increase relative to BASELINE in this group of patients was 218 + 12 and +5 + 4%, respectively, and six of eight (75%) patients were considered CRT responders. All patients improved from NYHA functional class III to class II.
MultiPoint
TM Pacing programming
Left ventricular vector combinations and pacing delays for MPP programmed at the end of the 12-month visit are shown in Table 2 . The LV1 cathode was D1 in eight of eight (100%) patients, whereas the LV2 cathode was P4 in three of eight (37.5%) patients, M3 in two of eight (25%) patients, and M2 in three of eight (37.5%) patients.
Changes in echocardiographic and clinical findings after 4 months of MultiPoint TM Pacing
After 4 months of MPP, the ESV reduction and EF increase relative to baseline was significantly improved compared with after 12 months of conventional CRT (ESV: 231 + 18%, P ¼ 0.048; EF: +13 + 8%, P ¼ 0.017, see Figure 1 ). New York Heart Association functional class improved to class I in three of eight (37.5%) patients and remained at class II in the remaining five of eight (62.5%) patients. Patient characteristics and follow-up measurements from all patients are shown in Table 3 .
The two patients classified as non-responders to conventional CRT at the 12-month exam both became responders with MPP while experiencing an additional reduction in ESV of 233 and 220% and an improvement in EF of +15 and +4% relative to the 12-month exam (Figure 2) .
The remaining six patients classified as responders to conventional CRT experienced additional reduction in ESV of 213 + 21% and improvement in EF of +7 + 7% relative to the 12-month exam after switching to MPP. Five of the six responders to conventional CRT remained responders with MPP, with four patients experiencing additional ESV change of at least 210%. One of the six responders to 12 months of conventional therapy experienced ESV increase from 137 to 159 mL and EF decrease from 35 to 31% and was considered a non-responder with MPP (see Patient 3 in Table 3 ). 
Discussion
MultiPoint
TM Pacing delivered through a quadripolar LV lead has thus far been shown to provide acute benefit as measured by LV dP/dt Max , 9 LV dyssynchrony, 11 LV peak radial strain, 12 LV PV loop parameters, 10 and LV electrical activation. 19 Additionally, our recent work has suggested mid-term improvement in LV reverse remodelling and LV function with MPP over conventional CRT. 13 However, previous evaluations of MPP have focussed on patients receiving de novo CRT implants. In this study, we evaluated the role of programming settings to deliver MPP in patients already receiving conventional CRT and observed further improvements in LV ESV and LV EF beyond that seen with conventional CRT. Previous work has demonstrated an acute and chronic benefit of biventricular pacing with MPP in a single CS branch when compared with conventional CRT in de novo CRT implants. An early feasibility study utilizing pressure wire measurements by Thibault et al. in 21 patients showed an increase in LV dP/dt Max with MPP compared with simultaneous biventricular pacing. 9 In a multicentre study using tissue Doppler imaging and speckle tracking echocardiography, Rinaldi et al. demonstrated an improvement in acute mechanical LV dyssynchrony 11 and in acute global peak LV radial strain 12 during delivery of MPP. A recent study of 15 patients compared MPP in a single CS branch with multisite LV pacing with two leads in two different CS branches and found no difference in acute LV dP/dt Max improvement between the two dual LV pacing modalities, which both offered significant improvement over baseline pacing. 19 In a study evaluating intraoperative LV haemodynamics, our group reported significant improvement in systolic and diastolic parameters during the best tested MPP intervention relative to the best tested conventional BiV pacing intervention using PV loop analysis. 10 After randomization to receive biventricular pacing with MPP or conventional CRT optimized by PV loop measurements, mid-term follow-up results showed greater reduction in LV ESV and improvement in LV EF in the MPP group. 13 While prior studies of MPP delivered from a single CS branch have focussed on de novo CRT implants, the effect of adding a second LV pacing site to patients with a previously implanted CRT system has been evaluated in the V3 trial. 20 Non-responders to conventional CRT for at least 6 months were randomized to receive triple-site ventricular pacing with the addition of a second LV lead or continue with conventional biventricular pacing. After 12 months, the group receiving a second LV lead showed no improvement relative to the conventional CRT group in the primary endpoint of clinical composite score or in secondary endpoints including echocardiographic indices of remodelling.
In the current study, we evaluated the addition of a second LV pacing site by activating MPP in both responders and non-responders to 12 months of conventional biventricular pacing. We observed significant improvement in LV reverse remodelling and LV function after 4 months of MPP compared with the improvement after 12 months of conventional CRT in our patient population. In particular, the two patients identified as non-responders to Switch from conventional CRT to multipoint LV pacing A15
conventional CRT became responders after switching to MPP using the definition of response of ESV decrease ≥15%. These preliminary results in a small group of patients suggest the role of MPP as a possible strategy to convert non-responder patients to responders and/or to further improve response in patients already responding to the conventional therapy. If confirmed in larger trials, these findings may be valuable for improving CRT outcomes.
Limitations
This study represents the experience of a single centre in a non-randomized feasibility study including a small number of patients with a limited follow-up duration after activation of MPP. The results should be interpreted with caution due to the small study population and must be confirmed in larger, randomized trials.
Conclusions
Multipoint LV pacing, when activated in patients with a preexisting CRT device, may provide additional benefits beyond those gained from conventional biventricular pacing. In a small, non-randomized study population, we observed significant improvements in LV end-systolic volume and LV EF after activation of MPP in a combined group of both responders and non-responders to 12 months of conventional CRT. Our results suggest that activating MPP may be a potential strategy to convert non-responder patients to responders or to further improve response in patients already responding to the conventional therapy.
Further randomized studies are needed to confirm these observations in a larger population. 
